CytoMed Therapeutics Limited

NasdaqCM GDTC

CytoMed Therapeutics Limited Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 8.27 M

CytoMed Therapeutics Limited Net Cash Used Provided By Financing Activities is USD 8.27 M for the year ending December 31, 2023, a 1,049.88% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

CytoMed Therapeutics Limited Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 719.62 K, a -76.68% change year over year.
CytoMed Therapeutics Limited Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 3.09 M, a 116.88% change year over year.
CytoMed Therapeutics Limited Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 1.42 M, a 117.73% change year over year.
CytoMed Therapeutics Limited Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 653.50 K.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqCM: GDTC

CytoMed Therapeutics Limited

CEO	Mr. Chee Kong Choo
IPO Date	April 14, 2023
Location	Singapore
Headquarters	1 Commonwealth Lane, No. 08-22
Employees	28
Sector	Healthcare
Industries Biotechnology 3D Printing Robotics

Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

Key trends

Past 5 years